Sanofi to Acquire Bioverativ to Treat Hemophilia

 Sanofi to Acquire Bioverativ to Treat Hemophilia

Sanofi Reports Results of Cablivi (caplacizumab) in P-III HERCULES Study in Patients with Rare Blood Clotting Disorder, Published in NEJM


  • Sanofi acquires Bioverativ, in all stock transaction with its Eloctate & Alprolix products. Bioverativ to receive $105/share in cash for a premium of 64 % with total deal value as $11.6B
  • The focus of the agreement is to combine Bioverativ’s expertise with its platform for the advancement of fitusiran to treat Hemophilia A and B and further strengthening Sanofi’s footprints in rare diseases
  • Fitusiran is a once-monthly RNA interference (RNAi) therapeutic, targeted for hemophilia A and B with and without inhibitors

Click here read full press release/ article | Ref: Eli Lilly | Image: The Street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post